ABSCI CORP (ABSI)
US00091E1091 - Common Stock
Taking everything into account, ABSI scores 3 out of 10 in our fundamental rating. ABSI was compared to 561 industry peers in the Biotechnology industry. The financial health of ABSI is average, but there are quite some concerns on its profitability. ABSI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ABSI had negative earnings in the past year.
ABSI had a negative operating cash flow in the past year.
In the past 5 years ABSI always reported negative net income.
ABSI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -41.52%, ABSI is in line with its industry, outperforming 55.14% of the companies in the same industry.
ABSI has a Return On Equity of -48.51%. This is in the better half of the industry: ABSI outperforms 67.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.52% | ||
| ROE | -48.51% | ||
| ROIC | N/A |
ROA(3y)-35.93%
ROA(5y)-57.21%
ROE(3y)-43.06%
ROE(5y)-81.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ABSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABSI has more shares outstanding
The debt/assets ratio for ABSI has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.88 indicates that ABSI is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.88, ABSI is doing good in the industry, outperforming 74.77% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that ABSI is not too dependend on debt financing.
The Debt to Equity ratio of ABSI (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.88 |
ROIC/WACCN/A
WACC10.69%
2.3 Liquidity
ABSI has a Current Ratio of 5.63. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
ABSI has a Current ratio of 5.63. This is comparable to the rest of the industry: ABSI outperforms 58.92% of its industry peers.
ABSI has a Quick Ratio of 5.63. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
ABSI has a Quick ratio (5.63) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.63 | ||
| Quick Ratio | 5.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.48% over the past year.
ABSI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.38%.
The Revenue has been growing slightly by 6.15% on average over the past years.
EPS 1Y (TTM)19.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-39.38%
Revenue growth 3Y6.15%
Revenue growth 5YN/A
Sales Q2Q%128.63%
3.2 Future
ABSI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.12% yearly.
The Revenue is expected to grow by 55.01% on average over the next years. This is a very strong growth
EPS Next Y22.54%
EPS Next 2Y14.41%
EPS Next 3Y12.02%
EPS Next 5Y9.12%
Revenue Next Year-4.96%
Revenue Next 2Y60.11%
Revenue Next 3Y553.14%
Revenue Next 5Y55.01%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ABSI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABSI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ABSI's earnings are expected to grow with 12.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.41%
EPS Next 3Y12.02%
5. Dividend
5.1 Amount
No dividends for ABSI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ABSCI CORP
NASDAQ:ABSI (1/8/2025, 8:00:00 PM)
After market: 2.98 -0.24 (-7.45%)3.22
+0.15 (+4.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners60.53%
Inst Owner Change0%
Ins Owners7.81%
Ins Owner Change-0.19%
Market Cap369.85M
Analysts81.33
Price Target8.51 (164.29%)
Short Float %15.42%
Short Ratio7.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.87%
Min EPS beat(2)-13.12%
Max EPS beat(2)-10.61%
EPS beat(4)0
Avg EPS beat(4)-6.67%
Min EPS beat(4)-13.12%
Max EPS beat(4)-1.23%
EPS beat(8)1
Avg EPS beat(8)-12.44%
EPS beat(12)1
Avg EPS beat(12)-11.01%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.79%
Min Revenue beat(2)-34.7%
Max Revenue beat(2)-4.87%
Revenue beat(4)0
Avg Revenue beat(4)-41.35%
Min Revenue beat(4)-67.78%
Max Revenue beat(4)-4.87%
Revenue beat(8)1
Avg Revenue beat(8)-39.83%
Revenue beat(12)2
Avg Revenue beat(12)-34.2%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.73%
PT rev (3m)4.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.55%
EPS NY rev (1m)0.8%
EPS NY rev (3m)-8.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-13.21%
Revenue NY rev (1m)1.36%
Revenue NY rev (3m)-1.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 87.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.84 | ||
| P/tB | 2.38 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0.04
BVpS1.75
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.52% | ||
| ROE | -48.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-35.93%
ROA(5y)-57.21%
ROE(3y)-43.06%
ROE(5y)-81.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.94% | ||
| Cap/Sales | 9.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.63 | ||
| Quick Ratio | 5.63 | ||
| Altman-Z | 2.88 |
F-Score4
WACC10.69%
ROIC/WACCN/A
Cap/Depr(3y)234.14%
Cap/Depr(5y)223.96%
Cap/Sales(3y)364.15%
Cap/Sales(5y)238.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y22.54%
EPS Next 2Y14.41%
EPS Next 3Y12.02%
EPS Next 5Y9.12%
Revenue 1Y (TTM)-39.38%
Revenue growth 3Y6.15%
Revenue growth 5YN/A
Sales Q2Q%128.63%
Revenue Next Year-4.96%
Revenue Next 2Y60.11%
Revenue Next 3Y553.14%
Revenue Next 5Y55.01%
EBIT growth 1Y-14.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.02%
EBIT Next 3Y11.57%
EBIT Next 5YN/A
FCF growth 1Y31.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.88%
OCF growth 3YN/A
OCF growth 5YN/A